MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific DSO Ratio 2011-2026 | TMO
Annual DSO Ratio Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70 | 69.9 | 69.6 | 65.4 | 63.8 | 57.2 | 70.8 | 62 | 75.2 | 68.4 | 54.8 | 53.5 | 54.2 | 52.7 | 56.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 75.2 | 52.7 | 62.9 |
Quarterly DSO Ratio Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.8 | 71.7 | 73.6 | 69.7 | 68.7 | 71.9 | 70.7 | 68.1 | 68.3 | - | 32.8 | 32.8 | 61.2 | - | 54 | 54.3 | 52 | - | 61.5 | 75.7 | 73.9 | 58.1 | 63.3 | 62.8 | 63.2 | 58 | 63.8 | 62.1 | 62.5 | 58.5 | 69.2 | 70.9 | 66.3 | 56.2 | 61.9 | 61.3 | 59.4 | 49.9 | 56.3 | 54.4 | 58.4 | 50.2 | 54.1 | 52.2 | 51.6 | 51.1 | 55.5 | 54.7 | 53.6 | 50.5 | 53.4 | 53 | 53.3 | 52.1 | 55.2 | 57.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 75.7 | 32.8 | 59.4 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
63.8 | $ 116.98 | 2.73 % | $ 35.6 B | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
49.2 | $ 25.38 | 2.19 % | $ 705 M | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
55.3 | $ 196.17 | 2.7 % | $ 140 B | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 16.27 | 2.23 % | $ 492 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.97 | 1.7 % | $ 958 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
46.1 | $ 94.63 | 1.43 % | $ 11.9 B | USA |
 |
DexCom
DXCM
|
87 | $ 65.54 | 3.85 % | $ 25.6 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
31.7 | $ 16.28 | 1.18 % | $ 178 M |  China |
 |
Co-Diagnostics
CODX
|
94.7 | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 109.05 | 1.76 % | $ 8.99 B |  Irlanda |
 |
Illumina
ILMN
|
61.3 | $ 128.09 | 1.3 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 174.65 | 2.42 % | $ 30 B | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 80.09 | 2.57 % | $ 5.41 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 176.44 | 4.03 % | $ 8.75 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K |  Israel |
 |
Medpace Holdings
MEDP
|
50.4 | $ 524.94 | 3.23 % | $ 15.1 B | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 318.47 | 3.81 % | $ 27.2 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.84 | 2.0 % | $ 448 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 8.37 | 3.85 % | $ 1.07 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 14.52 | -0.08 % | $ 1.88 B | USA |
 |
Natera
NTRA
|
81.5 | $ 212.81 | 1.69 % | $ 20.9 B | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.49 | 3.12 % | $ 447 M | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Precipio
PRPO
|
21.1 | $ 27.77 | -2.56 % | $ 44.6 M | USA |
 |
Quotient Limited
QTNT
|
45.1 | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Personalis
PSNL
|
55.8 | $ 6.48 | 5.02 % | $ 384 M | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 274.08 | 1.83 % | $ 22.8 B | USA |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.68 | -0.37 % | $ 87 K | USA |
 |
Biomerica
BMRA
|
57.7 | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
BioNano Genomics
BNGO
|
63.7 | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Interpace Biosciences
IDXG
|
66.9 | $ 2.0 | 0.25 % | $ 8.85 M | USA |